MYRIAD GENETICS INC
MYGNMyriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (precision medicine), assess a patient's risk of disease progression and disease recurrence (precision medicine), and measure disease activity.
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Active comparator: Niraparib | Phase 3 | Ovarian Neoplasms | - | - |
Oral rucaparib | Phase 2 | Ovarian Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in MYRIAD GENETICS INC's drug pipeline?→
CatalystAlert tracks 2 drug candidates in MYRIAD GENETICS INC's (MYGN) pipeline across Phase 3, Phase 2. Its lead program is Active comparator: Niraparib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MYRIAD GENETICS INC's next FDA catalyst?→
MYRIAD GENETICS INC's (MYGN) next tracked catalyst is a Earnings expected November 2, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MYGN biotech catalysts?→
Add MYGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MYRIAD GENETICS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.